Entrada Therapeutics Announced Preliminary Data From Its Phase 1 Trial For ENTR-601-44-101 In Healthy Volunteers, On Track To Submit Regulatory Applications In Q4 2024 To Initiate Separate Two Phase 2 Trials In Duchenne Muscular Dystrophy Patients
$TRDA
Biotechnology: Pharmaceutical Preparations
Health Care
- ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs, ECGs, physical exams or laboratory assessments.
- ENTR-601-44 demonstrated significant plasma concentration, muscle concentration and exon skipping, at levels that suggest the potential for a clinically meaningful starting dose in planned upcoming patient trials.
- Phase 2 planning underway for separate ENTR-601-44 and ENTR-601-45 clinical trials with regulatory filings anticipated in Q4 2024